Labcorp Holdings Inc.

NYSE:LH

Medical - Diagnostics & Research

Healthcare
$370.78 -1.33%

-$3.46 today

Market cap
$30.11B
Beta
0.88
P/E (TTM)
22.4
EPS (TTM)
$11.44
Dividend yield
1.12%
52W Low $241.81High $293.72

Volume 0.69M

Average 0.63M

LH Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Labcorp Holdings Inc.NYSE: LH

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit grows in line with its trailing trend

Q2 FY2026 gross profit of $1.11B rose 6.3% year over year, ahead of the +5.3% change in trailing-twelve-month gross profit. Sequentially, it rose 18.5% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Gross profit amounted to 26.8% of revenue in FY2025, down 1.1 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +6.3% holds above the trailing-twelve-month pace of +5.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.11B+18.5% QoQ
Last fiscal yearDec 2025
$3.73B+3.0% YoY
LTMJun 2026
$4B+5.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.3%——
1 year+3.0%——
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
3.73B USD
Year-over-year change
+3.0%
4-year CAGR
-7.0%

Gross Profit vs competitors

How LH compares with its peers on the latest reported figures

  • LH's LTM Jun 2026 gross profit of $4B is the 2nd highest of the 7 companies compared; the peer median is $1.53B.
  • Its year-over-year change of +5.3% is the 6th highest of 7, against a peer median of +27.0%.
  • Gross profit amounts to 27.8% of revenue for LH, versus a peer median of 51.6%.
LH Competitors Peer median
Gross Profit for LH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$19.62B +10.8%-1.4%41.4%
LHLabcorp Holdings Inc.LTM Jun 2026$4B +5.3%+0.2%27.8%
DGXQuest Diagnostics IncorporatedLTM Sep 2026$3.93B +8.6%+0.9%33.1%
NTRANatera, Inc.LTM Jun 2026$1.77B +43.1%+60.2%65.3%
QGENQiagen N.V.LTM Jun 2026$1.3B +1.1%-2.3%61.8%
GHGuardant Health, Inc.LTM Sep 2026$833.7M +44.9%+29.2%65.2%
GRALGRAIL, Inc.LTM Jun 2026-$17.89M +76.4%—10.8%
Peer median (excluding LH) $1.53B+27.0%+0.9%51.6%

Competitors are the stored peer set for LH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.14B11.86B12.16B13.01B13.95B
Cost of Revenue8.14B8.16B8.8B9.38B10.22B
Gross Profit4.99B3.71B3.36B3.62B3.73B
Gross Margin38.0%31.3%27.7%27.9%26.8%
Research & Development002M00
Selling, General & Admin1.69B2B2.02B2.23B2.22B
Operating Expenses1.94B2.27B2.64B2.54B2.22B
Depreciation & Amortization577M537.2M577.3M643.5M681.1M
EBITDA3.68B1.95B1.35B1.81B2.01B
EBITDA Margin28.0%16.5%11.1%13.9%14.4%
Operating Income3.05B1.44B725.6M1.09B1.52B
Operating Margin23.2%12.1%6.0%8.4%10.9%
Interest Income000015.2M
Interest Expense211.8M179.8M199.6M208.3M224.1M
Other Income / Expenses(161M)(199.1M)(156.7M)(127.2M)(408.7M)
Income Before Tax2.89B1.24B568.9M959.5M1.11B
Pre-Tax Margin22.0%10.4%4.7%7.4%7.9%
Income Tax Expense690M233.9M188.5M212.4M229.8M
Net Income2.38B1.28B418M746M876.5M
Net Margin18.1%10.8%3.4%5.7%6.3%
EPS (Basic)24.5814.044.808.8910.54
EPS (Diluted)24.3813.964.778.8410.46
Weighted Avg Shares96.7M91.1M87.1M83.9M83.2M
Weighted Avg Shares (Diluted)97.5M91.6M87.6M84.4M83.8M

Labcorp Holdings Inc.

NYSE:LH

Intrinsic Alpha fair value

Locked

Current Price

$370.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.